Mirvetuximab soravtansine is an antibody-drug concatenation (ADC) containing a folate receptor alpha (fralpha)-conjugated antibody, a cleavable junction, and the medenosine alkaloid DM4, a potent microtubulin-targeting agent, that can be used in studies related to platinum-resistant epithelial ovarian cancer (EOC).
Molecular Weight:
977.59
Purity:
>98.0%
CAS Number:
[1453084-37-1]
Formula:
C42H61ClN4O14S3
Target:
ADC Linker
* VAT and and shipping costs not included. Errors and price changes excepted